Theravance Biopharma (TBPH) Leases (2019 - 2025)
Historic Leases for Theravance Biopharma (TBPH) over the last 7 years, with Q3 2025 value amounting to $25.4 million.
- Theravance Biopharma's Leases fell 1324.06% to $25.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.4 million, marking a year-over-year decrease of 1324.06%. This contributed to the annual value of $28.4 million for FY2024, which is 2186.18% down from last year.
- Per Theravance Biopharma's latest filing, its Leases stood at $25.4 million for Q3 2025, which was down 1324.06% from $26.5 million recorded in Q2 2025.
- Theravance Biopharma's Leases' 5-year high stood at $42.5 million during Q1 2021, with a 5-year trough of $25.4 million in Q3 2025.
- For the 5-year period, Theravance Biopharma's Leases averaged around $35.8 million, with its median value being $38.5 million (2023).
- Per our database at Business Quant, Theravance Biopharma's Leases skyrocketed by 109.85% in 2022 and then plummeted by 2243.52% in 2025.
- Theravance Biopharma's Leases (Quarter) stood at $39.7 million in 2021, then rose by 1.1% to $40.1 million in 2022, then decreased by 9.57% to $36.3 million in 2023, then decreased by 21.86% to $28.4 million in 2024, then fell by 10.24% to $25.4 million in 2025.
- Its Leases stands at $25.4 million for Q3 2025, versus $26.5 million for Q2 2025 and $27.4 million for Q1 2025.